Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCE Perfusion Imaging in HCM
NCT02560467Unknown
- Sponsor
- Oregon Health & Science University
- Start
- Dec 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of perflutren lipid microspheres and sulfur hexafluoride in hypertrophic cardiomyopathy (HCM), sponsored by Oregon Health & Science University. Primary endpoints: Myocardial perfusion in the hypertrophied segment and Myocardial blood flow reserve in the hypertrophied segment. Status: unknown.
02
Drugs
perflutren lipid microspheressulfur hexafluoride
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02560467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560467.